

# Myeloneuropathy from Nitrous Oxide Abuse: Unusually High Methylmalonic Acid and Homocysteine Levels

Andrew J. Waclawik, MD; Christopher C. Luzzio, MD; Katalin Juhasz-Pocsine, MD;  
Valerie Hamilton, RN

## ABSTRACT

A 23-year-old patient developed diffuse paresthesias and sensory loss. He had mildly reduced serum vitamin B<sub>12</sub> (B<sub>12</sub>) concentration with unusually high levels of methylmalonic acid (MMA) and homocysteine and no evidence of B<sub>12</sub> malabsorption. Following parenteral B<sub>12</sub> administration, his neurological deficit promptly resolved and B<sub>12</sub> and MMA levels normalized, but elevated levels of homocysteine persisted. One year later, he admitted to inhaling nitrous oxide (N<sub>2</sub>O). After halting N<sub>2</sub>O abuse his homocysteine level normalized. This case demonstrates the importance of serum homocysteine level measurements in cases of suspected N<sub>2</sub>O toxicity.

## INTRODUCTION

Nitrous oxide abuse is relatively common<sup>1,2</sup> and may cause significant neurological disability. The mechanism of N<sub>2</sub>O neurotoxicity is interference with vitamin B<sub>12</sub> bioavailability<sup>3</sup> and the resulting neurological syndromes are indistinguishable from B<sub>12</sub> deficiency due to malabsorption or low dietary intake.<sup>4-6</sup>

Diagnosing N<sub>2</sub>O-induced neurologic disease may be difficult if the affected patient does not disclose his inhalation activity, or the examiner fails to inquire about it. Serum concentrations of methylmalonic acid (MMA) and homocysteine are sometimes the only clues about the N<sub>2</sub>O exposure since vitamin B<sub>12</sub> levels may be normal.<sup>6</sup>

## CASE REPORT

A 23-year-old man described 6-8 weeks of progressive numbness and paresthesias affecting his hands and feet.

---

Authors are with the Department of Neurology, University of Wisconsin Medical School, Madison, Wis. Address correspondence to Andrew J. Waclawik, MD, Associate Professor of Neurology, Dept of Neurology, CSC H6/574, UW Medical School, 600 Highland Ave, Madison, Wis 53792; 608.263.7539; fax: 608.265.0172; e-mail: waclawik@neurology.wisc.edu.


He denied any weakness, difficulty walking, bowel or bladder dysfunctions, or cognitive problems.

Approximately 2 weeks prior to the onset of his symptoms he began taking carbamazepine for mood control. His psychiatrist initially ascribed his symptoms to possible carbamazepine toxicity but his paresthesias progressed despite the discontinuation of carbamazepine.

His medical history included schizoaffective disorder but he had not used psychotropic medications for over a year. Close family members were free of neurodegenerative conditions. He denied toxic exposure or any substance abuse, but admitted using some "street drugs" in the past. He tested negative for HIV on several occasions. He ate a regular diet.

On neurological examination, his mental status, speech, and cranial nerves were normal. Motor examination showed normal muscle bulk, tone, and power. Muscle stretch reflexes were normal. Sensory examination showed markedly decreased vibratory sensation in his feet and legs, in a stocking pattern, normal proprioception, and no significant abnormality of pain, temperature, and light touch sensations. His Romberg test was negative, but he had slight difficulty on tandem gait testing.

Nerve conduction study and needle electromyography were normal, but quantitative sensory testing (QST) showed markedly abnormal thresholds for vibratory stimuli in lower extremities with normal thresholds for thermal stimuli. Complete blood count was normal except for mild increase in mean corpuscular volume at 96 fl/RBC (82-95). Serum creatinine, blood urea nitrogen, hemoglobin A<sub>1c</sub>, aspartate aminotransferase, alanine aminotransferase, electrolytes, and serum protein electrophoresis were normal. Venereal Disease Research Laboratory test and Lyme titer were negative. ANA titer was minimally elevated at 1:40. Red blood cell folate level was normal at 444



**Figure 1A, B.** Vitamin B<sub>12</sub>-dependent metabolic pathways.

ng/ml (145-500). Serum B<sub>12</sub> level was mildly below normal level at 136 pg/ml (150-800). There was severe elevation of MMA at 4.1µmo/l (0.0-.4). Homocysteine level was also very elevated at 114 µmol/l (4-20). Schilling test was normal. Anti-parietal cell and anti-intrinsic factor antibodies were negative. Magnetic resonance imaging of the head was normal.

The patient was prescribed intramuscular B<sub>12</sub> injections with a 1000 µg dose daily for 5 days and then 1000 µg every 3 to 4 weeks. His symptoms completely resolved within a few weeks after initiation of B<sub>12</sub> supplementation and his neurological examination 8 weeks later was normal. His B<sub>12</sub> and MMA levels normalized within 2 months, but very high homocysteine levels persisted and unexpectedly rose to 164 µmol/l (10 times upper range of normal). The patient remained asymptomatic with intramuscular (IM) B<sub>12</sub> treatment for a number of months, but subsequently he admitted inhaling, daily, large amounts of N<sub>2</sub>O from cartridges used as propellants for decoration of baked goods. For several months before his symptoms developed he inhaled N<sub>2</sub>O from between 24 to 60 cartridges per day, and on some weekends he would expend up to 240 cartridges. He complied with advice to halt N<sub>2</sub>O abuse and his homocysteine level was normal on a follow-up visit 4 weeks later. Following the change to oral vitamin B complex supplementation (1

tablet twice a day) his B<sub>12</sub>, MMA, and homocysteine levels remained normal and on subsequent follow-up visits he continued to be symptom free with normal neurological examination.

## DISCUSSION

Nitrous oxide oxidizes the B<sub>12</sub> (cobalamin) cobalt atom from its 1+ to 3+ valence state, rendering methylcobalamin (one of the active forms of cobalamin) inactive as a cofactor of methionine synthase.<sup>3</sup> This inhibits conversion of homocysteine to methionine (Figure 1A), a precursor of S-adenosylmethionine, which is necessary for myelin production, and also inhibits production of tetrahydrofolate (Figure 1A) which is essential for DNA synthesis.<sup>3,6</sup> Functional B<sub>12</sub> (5'-deoxyadenosylcobalamin) is also necessary for conversion of methylmalonyl CoA to succinyl CoA (Figure 1B). Biochemical indicators of B<sub>12</sub> deficiency are elevated serum concentrations of homocysteine and MMA, a result of their impaired metabolism.

The neurological syndromes caused by N<sub>2</sub>O toxicity may occur in two different clinical situations. A subgroup of patients develop symptoms after prolonged, repeated exposure (usually abuse), and those patients typically have normal B<sub>12</sub> levels. Another group are patients who usually have mild, subclinical B<sub>12</sub> deficiency, and may become symptomatic after even a single exposure to N<sub>2</sub>O.<sup>6</sup> The diagnosis of the N<sub>2</sub>O toxicity syndromes may be elusive in patients presenting with normal serum B<sub>12</sub> unless N<sub>2</sub>O exposure is noted. Elevated MMA and homocysteine levels may be the only clues indicating disturbed B<sub>12</sub> metabolism in these patients.

The patient in this report presented with paresthesias, profound loss of vibratory sensation ("large fiber" sensory loss) and preservation of pain and temperature ("small fiber" function). This clinical pattern, confirmed by QST, with unremarkable nerve conduction studies, suggested that his neurologic deficit was caused predominantly by dysfunction of the posterior columns of the spinal cord. Coexisting peripheral nerve involvement, below the detection threshold of the nerve conduction studies technique, was likely, with mostly distal sensory deficit. Therefore, his neurological syndrome could be referred to as myeloneuropathy.

The high MMA and homocysteine levels indicated that impaired B<sub>12</sub> metabolism was the culprit of the neurological deterioration. Moreover, his symptoms completely resolved with high dose parenteral B<sub>12</sub> administration. However, the persistent homocysteine levels remained unexplained until finally the patient ad-

mitted, on subsequent evaluations, chronic N<sub>2</sub>O abuse. Once the patient quit N<sub>2</sub>O inhalation, the homocysteine levels promptly normalized.

Mildly low level of B<sub>12</sub> on initial measurement in our patient is of uncertain cause since N<sub>2</sub>O should not compromise the absorption of B<sub>12</sub>, his Schilling test was normal, and there was no dietary deficiency. We cannot rule out entirely impaired food-B<sub>12</sub> absorption since the chicken serum test was not performed.<sup>7</sup> It is also possible that the oxidation of the B<sub>12</sub> cobalt core might have interfered with the immunoassay employed in B<sub>12</sub> level measurement by changing the configuration of the cobalamin molecule.

Interestingly, a similar case was reported in 1978 by Sahenk et al,<sup>1</sup> who described a patient inhaling whipped cream propellant, although the authors did not associate N<sub>2</sub>O oxide toxicity with disturbance of B<sub>12</sub> metabolism. In 1997 Brett<sup>2</sup> described a 21-year-old patient with ataxia, weakness, sensory loss, Lhermitte's sign, and acute anxiety secondary to N<sub>2</sub>O toxicity from whipped cream bulbs (up to 200 per week). Similarly to our case, she had low serum B<sub>12</sub> level at 56ng/L (200-1000) despite normal Schilling test. She was successfully treated with intramuscular B<sub>12</sub>.

This is the first report documenting such high levels of homocysteine and methylmalonic acid levels in a patient with nitrous oxide abuse. It demonstrates the potential magnitude of metabolic derangement in N<sub>2</sub>O

abusers, and how challenging evaluation of these patients may be if they do not admit to substance abuse on initial evaluation.

As demonstrated in our patient, the homocysteine level appears to be more sensitive, and therefore a more useful biochemical marker of disturbed B<sub>12</sub> metabolism in cases of N<sub>2</sub>O toxicity than MMA. In our opinion this syndrome is probably underdiagnosed, and may be completely missed if homocysteine level is excluded in laboratory testing of these patients.

#### REFERENCES

1. Sahenk Z, Mendel JR., Couri D, et al. Polyneuropathy from inhalation of N<sub>2</sub>O cartridges through a whipped-cream dispenser. *Neurology*. 1978;28:485-487.
2. Brett A. Myeloneuropathy from whipped cream bulbs presenting as conversion disorder. *Aust N Z J Psychiatry*. 1997;31:131-132.
3. Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. *Neurology*. 1995;45:1435-1440.
4. Blanco G, Peters H.A. Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. *Arch Neurol*. 1983;40:416-418.
5. Marié RM, Le Biez E, Busson P, et al. Nitrous oxide anesthesia-associated myelopathy. *Arch Neurol*. 2000; 57:380-382.
6. Kinsella, LJ, Green R. "Anesthesia paresthetica": Nitrous oxide-induced cobalamin deficiency. *Neurology*. 1995;45:1608-1610.
7. Carmell R. Malabsorption of food cobalamin. *Baillieres Clin Hematol*. 1995;8:639-655.



The mission of the *Wisconsin Medical Journal* is to provide a vehicle for professional communication and continuing education of Wisconsin physicians.

The *WMJ* (ISSN 1098-1861) is the official publication of the Wisconsin Medical Society and is devoted to the interests of the medical profession and health care in Wisconsin. The managing editor is responsible for overseeing the production, business operation and contents of *WMJ*. The editorial board, chaired by the medical editor, solicits and peer reviews all scientific articles; it does not screen public health, socioeconomic or organizational articles. Although letters to the editor are reviewed by the medical editor, all signed expressions of opinion belong to the author(s) for which neither the *WMJ* nor the Society take responsibility. The *WMJ* is indexed in Index Medicus, Hospital Literature Index and Cambridge Scientific Abstracts.

For reprints of this article contact the *WMJ* Managing Editor at 866.442.3800 or e-mail [wmj@wismed.org](mailto:wmj@wismed.org).

© 2003 Wisconsin Medical Society